Nathan G. Kim

Nathan G. Kim

Auto-generated profile, based on publicly available information

Nathan G. Kim

Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2018 in Cancer
Verified
Journal Article
Open access
PDF file
NKNathan G. Kim
Nathan G. Kim
PNPauline P. Nguyen
Pauline P. Nguyen
HDHansen Dang
Hansen Dang
RKRadhika Kumari
Radhika Kumari
GGGabriel Garcia
Gabriel Garcia
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the few cancers whose incidence continues to increase. The goal of the current study was to investigate the presentation and survival trends of patients with HCC presenting to a university hospital between 1998 and 2015.METHODS: Study data were ascertained by individual chart review with survival data also supplemented by National Death Index query up to December 31, 2015. Patients were divided into three 6‐year groups by diagnosis date (1998‐2003, 2004‐2009, and 2010‐2015).RESULTS: A total of 2106 consecutive patients with HCC were included. The majority of patients had either hepatitis C (56.7%) or hepatitis B (22.1%), but cases of nonalcoholic steatohepatitis HCC increased by 68% over the most recent time period. Screening/surveillance identified 61% of HCC cases, but only 31% of these patients underwent curative treatment, which did not increase significantly over time. The overall median survival was 29.8 months (2.48 years) and without improvement over time. On multivariable analysis, Asian or Hispanic ethnicity, meeting Milan criteria, and receiving any of the standard HCC treatments were found to be significantly associated with improved survival, but diagnosis time period and liver disease etiology were not.CONCLUSIONS: Over the last 18 years, the percentage of cases of nonalcoholic steatohepatitis HCC has increased but not overall survival. It is interesting to note that only 31% of patients with HCC identified via screening/surveillance received any curative treatment. Further research is needed to better understand the barriers to curative care for patients with HCC and the causes of the lack of improvement in survival in the more recent patient cohort. Cancer 2018;124:2588‐98. © 2018 American Cancer Society.

1 July 2016 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
MLMaya R Ladenheim
Maya R Ladenheim
NKNathan G Kim
Nathan G Kim
PNPauline Nguyen
Pauline Nguyen
ALAn Le
An Le
MSMarcia L Stefanick
Marcia L Stefanick
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
Background Although sex differences in hepatocellular carcinoma (HCC) risk are well known, it is unclear whether sex differences also exist in clinical presentation and survival outcomes once HCC develops. Methods We performed a retrospective cohort study of 1886 HCC patients seen in a US medical centre in 1998–2015. Data were obtained by chart review with survival data also by National Death Index search. Results The cohort consisted of 1449 male and 437 female patients. At diagnosis, men were significantly younger than women (59.9±10.7 vs 64.0±11.6, p<0.0001). Men had significantly higher rates of tobacco (57.7% vs 31.0%, p<0.001) and alcohol use (63.2% vs 35.1%, p5 cm (30.2% vs 39.8%, p=0.001). Surgical and non-surgical treatment utilisation was similar for both sexes. Men and women had no significant difference in median survival from the time of diagnosis (median 30.7 (range=24.5–41.3) vs 33.1 (range=27.4–37.3) months, p=0.84). On multivariate analysis, significant predictors for improved survival included younger age, surgical or non-surgical treatment (vs supportive care), diagnosis by screening, tumour within Milan criteria and lower Model for End-Stage Liver Disease score, but not female sex (adjusted HR=1.01, CI 0.82 to 1.24, p=0.94). Conclusions Although men have much higher risk for HCC development, there were no significant sex differences in disease presentation or survival except for older age and lower tumour burden at diagnosis in women. Female sex was not an independent predictor for survival.

8 November 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
RSRiad Salem
Riad Salem
AKAllison J. Kwong
Allison J. Kwong
NKNathan Kim
Nathan Kim
DSDaniel Y. Sze
Daniel Y. Sze
NMNeil Mehta MD
Neil Mehta MD

1 June 2016 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
VCVincent Chen
Vincent Chen
ALAn Le
An Le
NKNathan G. Kim
Nathan G. Kim
LKLily H. Kim
Lily H. Kim
NNNghia H. Nguyen
Nghia H. Nguyen
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen

23 January 2026 in Journal of Hepatology
Verified
Journal Article
Closed access
NKNathan G. Kim
Nathan G. Kim
FYFrancis Y. Yao
Francis Y. Yao
AKAllison J. Kwong
Allison J. Kwong
NMNeil Mehta MD
Neil Mehta MD

1 April 2017 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
AKAlina Kutsenko
Alina Kutsenko
MLMaya R. Ba Ladenheim
Maya R. Ba Ladenheim
NKNathan Ba Kim
Nathan Ba Kim
PNPauline Ba Nguyen
Pauline Ba Nguyen
VCVincent Chen
Vincent Chen
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
Background: We used metabolic risk factors to estimate the prevalence and clinical significance of nonalcoholic fatty liver disease in Asian Americans with hepatocellular carcinoma (HCC). Methods: This is a retrospective cohort study of 824 consecutive Asian HCC patients at Stanford University Medical Center from 1998 to 2015. Patients were subdivided as: Chinese, other East Asian (Japanese and Korean), South East Asian (Vietnamese, Thai, and Laotian), Maritime South East Asian (MSEA: Malaysian, Indonesian, Filipino, and Singaporean), and South West Asian (Indian, Pakistani, and Middle Eastern). Metabolic risk factors studied were body mass index, hypertension, type II diabetes, and hyperlipidemia. Results: Most patients were male (76%) with mean age 63 years. Metabolic risk factors were highly prevalent on presentation and increased over time (P<0.001), as did the prevalence of cryptogenic HCC (P<0.004). Compared with other Asian subgroups, MSEAs had the highest body mass index (26.3) and higher rates of type II diabetes (44% vs. 23% to 35%, P=0.004), hypertension (59% vs. 38% to 55%, P=0.04), and cryptogenic HCC (15% vs. 4% to 10%, P=0.01). They were more likely to be symptomatic on presentation (44% vs. 32% to 58%, P=0.07), less likely to present within Milan criteria (34% vs. 35% to 63%, P<0.0001), and trended toward decreased 10-year survival rates compared with other ethnic subgroups (9% vs. 25% to 32%, P=0.07). Conclusions: Metabolic risk factors were increasingly prevalent among Asian Americans with HCC. MSEAs, who had the highest incidence of these risk factors, had more advanced tumor stage and trended toward worse survival.